SLC2A5 Correlated with Immune Infiltration: A Candidate Diagnostic and Prognostic Biomarker for Lung Adenocarcinoma

Table 1

Correlation of SLC2A5 mRNA expression and clinical prognosis in LUAD with different important clinical characteristics by Kaplan-Meier plotter.

Factor	Overall survival ()			Progression-free survival ()
		HR	value		HR	value
Sex
Female	317	1.15 (0.79-1.68)	0.4656	235	1.35 (0.85-2.12)	0.199
Male	344	1.46 (1.05-2.03)	0.0232	226	1.94 (1.25-3.03)	0.0028
Stage
1	370	1.62 (1.09-2.39)	0.0156	283	2.33 (1.41-3.86)	0.0007
2	136	0.75 (0.46-1.22)	0.2407	103	1.15 (0.67-2)	0.6103
3	24	1.46 (0.54-3.95)	0.4495	10	—	—
4	4	—	—	0	—	—
AJCC stage T
1	123	2.06 (1.11-3.83)	0.0188	47	1.37 (0.31-6.11)	0.6808
2	105	0.93 (0.54-1.6)	0.7933	93	0.86 (0.46-1.62)	0.6515
3	4	—	—	2	—	—
4	0	—	—	0	—	—
AJCC stage N
0	184	1.5 (0.93-2.42)	0.097	102	1.63 (0.75-3.55)	0.2142
1	44	0.73 (0.34-1.6)	0.4358	38	1.06 (0.43-2.62)	0.8979
2	3	—	—	2	—	—
AJCC stage M
0	231	1.55 (1.04-2.31)	0.0315	142	1.77 (0.99-3.18)	0.0514
1	1	—	—	0	—	—
Smoking history
Exclude those never smoked	246	2.68 (1.62-4.44)		243	2.05 (1.31-3.2)	0.0013
Only those never smoked	143	1.77 (0.78-4.06)	0.1686	143	2.32 (1.22-4.41)	0.0081

Bold values indicate .